OKYO Pharma's Chairman Acquires Shares, Positive Phase 2a Trial Results for Urcosimod in Neuropathic Corneal Pain

OKYO Pharma announced that Gabriele Cerrone, the Executive Chairman, has acquired 10,119 shares through Panetta Partners Limited, bringing his total holding to 10,526,416 shares. The company is developing investigational therapies for neuropathic corneal pain and inflammatory eye diseases. Urcosimod, a lipid conjugated chemerin peptide agonist, has shown anti-inflammatory and pain-reducing activities in mouse models and positive data in a Phase 2a trial for NCP pain reduction.